Key Takeaways
- VERIGRAFT, a Gothenburg-based clinical-stage biotech, secured $10 million from existing investors to initiate a pivotal Phase II/III clinical trial of its P-TEV (Personalized Tissue-Engineered Vein)
- P-TEV is a fully biological, donor-derived vein graft that is personalized using the patient’s own blood – eliminating the need for immunosuppression therapy, a first in vascular disease treatment
- The CVI treatment market is projected to reach USD 5,951 million by 2034, with 17.6 million diagnosed prevalent cases across leading markets in 2024
- Trial sites are active in Spain, the Netherlands, and Poland, and VERIGRAFT is targeting US and European market approval in 2028
Quick Recap
VERIGRAFT, a Swedish clinical-stage biotechnology company based in Gothenburg, announced on March 25, 2026 the initiation of a pivotal Phase II/III trial of its P-TEV therapy for patients suffering from chronic venous insufficiency (CVI), backed by USD 10 million from its existing investor base.
The official announcement was published via PRNewswire and flagged by venture intelligence account Parsers VC on X (formerly Twitter). The funding marks a critical inflection point for the company as it moves from safety trials toward the final regulatory hurdle before market launch.
What Is P-TEV and Why Does the Science Matter?
At the heart of this announcement is a technology that has been quietly maturing inside VERIGRAFT’s Gothenburg laboratories since the company was founded in 2014. P-TEV works by taking donor-derived venous material, stripping it of all donor cells through a process called decellularization, and then “personalizing” it using the receiving patient’s own blood to recellularize the scaffold.
The resulting graft is biologically integrated and patient-specific, meaning the immune system does not flag it as foreign tissue. This eliminates a long-standing problem in vascular surgery: the lifetime dependence on immunosuppressive drugs that weaken patients against infections and other diseases. The manufacturing process runs from start to finish in just 10 days, which is a significant engineering achievement for a personalized biological product.
VERIGRAFT’s platform is protected by 92 granted patents, giving it a formidable IP moat as it enters pivotal trials. In the preceding TECVI-1 safety trial, half the enrolled patients had already been treated, and the graft demonstrated maintained functionality at 12 months post-treatment, a milestone that cleared the final regulatory safety checkpoint needed to advance to Phase II/III. One patient in Spain, previously unable to walk without assistance, reportedly attended football matches unaided after receiving the P-TEV implant.
The Phase II/III trial now underway spans three countries: Spain, the Netherlands, and Poland. As an Advanced Therapy Medicinal Product (ATMP), the clinical program is designed to generate robust data in a limited patient population under EMA’s specialized regulatory framework, with the company targeting US and European market approval in 2028.
Market Context and Unmet Need
Chronic Venous Insufficiency is a progressive condition in which leg veins lose their ability to efficiently return blood to the heart, causing painful swelling, ulceration, and disability in millions of patients globally. The total CVI treatment market across the US, EU4, UK, and Japan was valued at approximately USD 2.1 billion in 2024, and is forecast to grow at a CAGR of 9.4% through 2034, driven by aging populations, obesity, and the introduction of emerging therapies.
No curative treatment currently exists for the deep venous form of CVI; standard of care is largely symptomatic, including compression stockings, endovenous ablation, and pharmaceutical venotonics. VERIGRAFT’s P-TEV is directly listed alongside VenoValve (enVVeno Medical), TR987 (TR Therapeutics), and SONOVEIN (Theraclion) as one of the pipeline therapies expected to reshape this market over the next decade.
The regenerative medicine field at large is experiencing a significant moment: Humacyte’s Symvess received FDA approval for vascular trauma in December 2024 and has since received U.S. Department of Defense funding, signaling growing institutional confidence in bioengineered vascular products. VERIGRAFT benefits from this tailwind as regulators and investors grow more comfortable with the ATMP class of biologics.
The broader artificial blood vessels market, which VERIGRAFT is positioned to enter, is growing from $2.17 billion in 2024 to an estimated $4.48 billion by 2030 at a CAGR of 12.8%, driven by failures of synthetic grafts and demand for more durable, biologically integrated solutions. The previous rounds for VERIGRAFT included a EUR 1.2 million Eurostars grant in early 2025 for the PREPPER 3D-printed arterial graft project, making this $10 million the company’s largest single raise to date and the one directly tied to its lead commercial product.
Competitive Landscape
VERIGRAFT vs. Closest Rivals in Biological Vascular Grafts
| Feature / Metric | VERIGRAFT (P-TEV) | enVVeno Medical (VenoValve) | Humacyte (Symvess / ATEV) |
| Core Technology | Decellularized + patient-blood-recellularized donor vein | Porcine bioprosthetic venous valve device | Decellularized human acellular tissue-engineered vessel (off-the-shelf) |
| Primary Indication | Chronic Venous Insufficiency (CVI) – deep vein valve failure | Deep venous disease (CVI), surgical valve repair | Vascular trauma; AV access for hemodialysis (BLA filing expected 2H 2026) |
| Immunosuppression Required | No – fully personalized, immune-tolerant | No (bioprosthetic) | No (decellularized, off-the-shelf) |
| Personalization Level | High – patient-specific recellularization using patient’s own blood | None – standardized device | None – universal, off-the-shelf |
| Manufacturing Lead Time | 10 days per patient | Ready to implant (standardized product) | Off-the-shelf (no patient-specific lead time) |
| IP Protection | 92 granted patents | Not publicly disclosed | Proprietary HAV platform (publicly traded) |
| Regulatory Stage | Phase II/III pivotal trial initiated March 2026; EU/US approval targeted 2028 | PMA under FDA supervisory appeal after not-approvable letter (as of late 2025) | FDA-approved for trauma (Dec 2024); BLA expansion for dialysis planned 2H 2026 |
| Funding Stage | Clinical-stage; $10M from existing investors (March 2026) | Nasdaq-listed (NVNO); $31M cash as of Q3 2025 | Nasdaq-listed (HUMA); $20M direct offering (March 2026) |
| Trial Geographies | Spain, Netherlands, Poland | US pivotal trial data | US commercial launch; 82+ hospitals eligible |
| Market Approval Target | 2028 (EU + US) | Pending FDA (appeal ongoing) | Approved in US for trauma; dialysis BLA targeted 2H 2026 |
Strategic Read
VERIGRAFT holds a distinct advantage in personalization depth: its graft is the only one that physically incorporates the patient’s own blood biology into the transplant structure, making immune rejection a near non-issue without compromising scalability due to its 10-day manufacturing window.
enVVeno Medical’s VenoValve directly addresses the same CVI deep-vein valve failure indication but is a standardized device awaiting FDA resolution after a not-approvable letter, placing its near-term commercial path under regulatory uncertainty.
Humacyte wins on commercial readiness and scalability: Symvess is already FDA-approved and shipping to hospitals, giving it a first-mover advantage in the US bioengineered vascular market, though its indications currently center on trauma and hemodialysis access rather than CVI.
Bayelsa Watch’s Takeaway
I will be direct: this is one of the more genuinely compelling clinical-stage biotech stories I have tracked in the regenerative medicine space in a while, and I think the $10 million figure actually undersells the significance of what is happening here. In my experience covering medtech and biotech fundraises, the size of the round is rarely the most important number.
What matters is what the capital is being used for, and in this case VERIGRAFT is using it to start a pivotal trial. That is the last clinical gate before a regulatory submission. They are not burning capital on proof-of-concept work or animal studies. They have already demonstrated 12-month graft functionality in a human safety trial and have a patient in Spain walking to football matches. That is compelling clinical evidence, not a slide deck.
